Balversa Gets Full FDA Approval for Locally Advanced, Metastatic Urothelial Carcinoma
January 19th 2024Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.
Radioligand Therapy Found to Improve Survival, Disease Progression in Advanced GEP-NETs
January 19th 2024Data presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium show first-line Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with advanced gastroenteropancreatic neuroendocrine tumors.
FDA to Evaluate Premarket Approval Application for TTFields in Non-Small Cell Lung Cancer
January 19th 2024Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.